Logo image
Rapid exacerbation of neuromyelitis optica after rituximab treatment
Journal article   Peer reviewed

Rapid exacerbation of neuromyelitis optica after rituximab treatment

Y. Dai, T. Lu, Y. Wang, L. Fang, R. Li, A.G. Kermode and W. Qiu
Journal of Clinical Neuroscience, Vol.26, pp.168-170
2016
url
Link to Published Version *Subscription may be requiredView

Abstract

Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.203 Neuromuscular Disorders
1.203.147 Multiple Sclerosis
Web Of Science research areas
Clinical Neurology
Neurosciences
ESI research areas
Neuroscience & Behavior
Logo image